Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN2 | Q96KS0 | 7/20 | 1.00 |
| ▸ | VHL | P40337 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | SLC11A2 | P49281 | 7/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.40 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4752168 | 0.83 | EGLN2 (0.70) | EGLN2VHLSLC11A2GAAMAPK1 | |
| SCHEMBL4752125 | 0.83 | EGLN2 (0.70) | EGLN2VHLSLC11A2KDM4EGAA | |
| SCHEMBL15445844 | 0.82 | EGLN2 (0.69) | EGLN2VHL | |
| SCHEMBL4752106 | 0.80 | EGLN2 (0.67) | EGLN2VHLSLC11A2KDM4EGAA | |
| SCHEMBL4752130 | 0.80 | EGLN2 (0.70) | EGLN2VHLSMN1; SMN2SLC11A2KDM4E | |
| SCHEMBL4752172 | 0.77 | EGLN2 (0.73) | EGLN2VHL | |
| SCHEMBL22199029 | 0.76 | EGLN2 (0.60) | EGLN2SMN1; SMN2SLC11A2KDM4E | |
| SCHEMBL4752140 | 0.76 | EGLN2 (0.62) | EGLN2VHLSMN1; SMN2SLC11A2KDM4E | |
| SCHEMBL4752115 | 0.74 | ALDH1A1 (0.66) | EGLN2VHLSLC11A2KDM4EGAA | |
| SCHEMBL2572956 | 0.72 | EGLN2 (0.67) | EGLN2VHLGAAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160229858-A1 | SUBSTITUTED DIHYDROPYRAZOLONES FOR TREATING CARDIOVASCULAR AND HEMATOLOGICAL DISEASES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-08-11 | — | — | US | disclosed |
| US-20160229858-A1 | SUBSTITUTED DIHYDROPYRAZOLONES FOR TREATING CARDIOVASCULAR AND HEMATOLOGICAL DISEASES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-08-11 | — | — | US | disclosed |
| US-9168249-B2 | Substituted dihydropyrazolones for treating cardiovascular and hematological diseases | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-10-27 | — | — | US | disclosed |
| US-9168249-B2 | Substituted dihydropyrazolones for treating cardiovascular and hematological diseases | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-10-27 | — | — | US | disclosed |
| US-20150148381-A1 | SUBSTITUTED DIHYDROPYRAZOLONES FOR TREATING CARDIOVASCULAR AND HEMATOLOGICAL DISEASES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-05-28 | — | — | US | disclosed |
| US-20150148381-A1 | SUBSTITUTED DIHYDROPYRAZOLONES FOR TREATING CARDIOVASCULAR AND HEMATOLOGICAL DISEASES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-05-28 | — | — | US | disclosed |
| US-8987261-B2 | Substituted dihydropyrazolones for treating cardiovascular and hematological diseases | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-03-24 | — | — | US | disclosed |
| US-8987261-B2 | Substituted dihydropyrazolones for treating cardiovascular and hematological diseases | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-03-24 | — | — | US | disclosed |
| US-8653111-B2 | Substituted dihydropyrazolones for treating cardiovascular and hematological diseases | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-02-18 | — | — | US | disclosed |
| US-8653111-B2 | Substituted dihydropyrazolones for treating cardiovascular and hematological diseases | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-02-18 | — | — | US | disclosed |
| US-20140031329-A1 | SUBSTITUTED DIHYDROPYRAZOLONES FOR TREATING CARDIOVASCULAR AND HEMATOLOGICAL DISEASES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-01-30 | — | — | US | disclosed |
| US-8389520-B2 | Substituted dihydropyrazolones for treating cardiovascular and hematological diseases | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-03-05 | — | — | US | disclosed |
| US-8389520-B2 | Substituted dihydropyrazolones for treating cardiovascular and hematological diseases | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-03-05 | — | — | US | disclosed |
| EP-2546253-A1 | SUBSTITUTED DIHYDROPYRAZOLONES FOR THE TREATMENT OF CARDIOVASCULAR AND HEMATOLOGICAL DISEASES | Bayer Intellectual Property GmbH (DE) | 2013-01-16 | — | — | EP | disclosed |
| US-20120121727-A1 | SUBSTITUTED DIHYDROPYRAZOLONES FOR TREATING CARDIOVASCULAR AND HEMATOLOGICAL DISEASES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-05-17 | — | — | US | disclosed |
| US-20120121727-A1 | SUBSTITUTED DIHYDROPYRAZOLONES FOR TREATING CARDIOVASCULAR AND HEMATOLOGICAL DISEASES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-05-17 | — | — | US | disclosed |
| EP-2383269-A2 | Substituted Dihydropyrazolones for the treatment of cardiovascular diseases | Bayer Pharma AG (DE) | 2011-11-02 | — | — | EP | disclosed |
| US-20100305085-A1 | SUBSTITUTED DIHYDROPYRAZOLONES FOR TREATING CARDIOVASCULAR AND HEMATOLOGICAL DISEASES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-12-02 | — | — | US | disclosed |
| US-20100305085-A1 | SUBSTITUTED DIHYDROPYRAZOLONES FOR TREATING CARDIOVASCULAR AND HEMATOLOGICAL DISEASES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-12-02 | — | — | US | disclosed |
| WO-2008067871-A1 | SUBSTITUTED DIHYDROPYRAZOLONES FOR TREATING CARDIOVASCULAR AND HAEMATOLOGICAL DISEASES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140031329-A1 | SUBSTITUTED DIHYDROPYRAZOLONES FOR TREATING CARDIOVASCULAR AND HEMATOLOGICAL DISEASES | THPO, PFKP, DCK | EGLN2 250/4885VHL 6/4885SMN1; SMN2 3249/4885 |
| US-20160229858-A1 | SUBSTITUTED DIHYDROPYRAZOLONES FOR TREATING CARDIOVASCULAR AND HEMATOLOGICAL DISEASES | THPO, PFKP, DCK | EGLN2 250/4885VHL 6/4885SMN1; SMN2 3249/4885 |
| US-20100305085-A1 | SUBSTITUTED DIHYDROPYRAZOLONES FOR TREATING CARDIOVASCULAR AND HEMATOLOGICAL DISEASES | THPO, PFKP, HPGDS | EGLN2 44/4885VHL 5/4885SMN1; SMN2 3514/4885 |
| US-20120121727-A1 | SUBSTITUTED DIHYDROPYRAZOLONES FOR TREATING CARDIOVASCULAR AND HEMATOLOGICAL DISEASES | THPO, PFKP, DCK | EGLN2 250/4885VHL 6/4885SMN1; SMN2 3249/4885 |
| US-20150148381-A1 | SUBSTITUTED DIHYDROPYRAZOLONES FOR TREATING CARDIOVASCULAR AND HEMATOLOGICAL DISEASES | THPO, PFKP, DCK | EGLN2 250/4885VHL 6/4885SMN1; SMN2 3249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.